Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial
<p><strong>Background</strong> Lung delivery of plasmid DNA encoding the CFTR gene complexed with a cationic liposome is a potential treatment option for patients with cystic fibrosis. We aimed to assess the efficacy of non-viral CFTR gene therapy in patients with cystic fibrosis.&...
Similar Items
-
A randomized, double-blind, placebo-controlled trial of repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis
by: Alton, E, et al.
Published: (2015) -
A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis
by: Alton, EWFW, et al.
Published: (2016) -
Self-reactive CFTR T cells in humans: implications for gene therapy.
by: Calcedo, R, et al.
Published: (2013) -
The safety and success rate of sputum induction using a low output ultrasonic nebuliser.
by: Hunter, C, et al.
Published: (1999) -
Fam83F induces p53 stabilisation and promotes its activity
by: Salama, M, et al.
Published: (2019)